<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146455</url>
  </required_header>
  <id_info>
    <org_study_id>ThirdXiangyaHCSU</org_study_id>
    <nct_id>NCT03146455</nct_id>
  </id_info>
  <brief_title>Thromboelastography Normal Reference Values in China Hunan Province</brief_title>
  <official_title>Establishment for Thromboelastography Normal Reference Values of Healthy Adults in China Hunan Province: A Multicenter Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changsha Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to establish the normal reference range of Thrombelastogram
      parameters in Hunan by a multicenter study, and to analyze the specificity of
      Thrombelastogram detection and the influence of gender, age and blood type on
      Thrombelastogram. The study will provide basic data and statistical basis for the
      establishment of normal reference range of Thrombelastogram in Hunan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thrombelastograghy (TEG) is an important test to assess the blood coagulation function to
      monitor the whole process of perioperative coagulation. TEG can evaluate the coagulation
      cascade, from platelet aggregation, clot strengthening and fibrin cross-linking to eventually
      clot lysis in small volume of whole blood. The reference range is one important element to
      influence the TEG results. At present, a number of studies have shown that reference range of
      TEG exists significant differences between different racial and geographic. At the same time,
      reagent manufacturers also suggested that each TEG laboratory should establish its own
      reference range. So it is important to establish our own reference range of TEG to guide the
      clinical blood transfusion and treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Actual">March 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>thromboelastography normal reference values</measure>
    <time_frame>2017.6.1-2017.12.1</time_frame>
    <description>The subjects with normal routine coagulation test results would be included.Thromboelastography was performed by using TEG-5000 TEG-CK (Hemostasis System, USA), and the parameters were recorded. Parameters includes R (coagulation reaction time, initial fibrin formation time), K (Coagulation time), α (α-angle, thrombosis rate), MA (maximum amplitude, absolute agglutination strength of reactive blood clot), LY30 (fibrinolysis rate with 30 min after MA determination) and CI (integrated coagulation index).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">498</enrollment>
  <condition>Coagulopathy</condition>
  <condition>Blood Transfusion Complication</condition>
  <arm_group>
    <arm_group_label>Health adults</arm_group_label>
    <description>(1) 18&lt; Age &lt;65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Health adults</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Permanent resident in Hunan, 18&lt; Age &lt;65.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1) 18&lt; Age &lt;65, and Han Chinese residents living in Hunan more than 3 years. (2) Health
        examination population who physical examination, assistant examination and serological
        examination were normal; Not suffer from other diseases last 3 months; Not take any
        medication last 7 days.

        Exclusion Criteria:

        1. Informed refusal. 2. Pregnancy, woman with menstrual period; volunteers who suffer from
        hematological system diseases such as hemorrhagic or thrombotic disease and take medicines
        that affect the function of blood coagulation (clopidogrel and aspirin, warfarin,
        rivaroxaban, dipyridamole, oral contraceptives, estrogen, antibiotics and traditional
        Chinese medicine related with blood coagulation, etc.) 3. Volunteers who have a history of
        liver disease, immune system disease, allergy and other disease within the last 3 months
        were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Third Xingya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pfanner G, Koscielny J, Pernerstorfer T, Gütl M, Perger P, Fries D, Hofmann N, Innerhofer P, Kneifl W, Neuner L, Schöchl H, Kozek-Langenecker SA; Austrian Society for Anaesthesia, Resuscitation and Intensive Care. [Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care]. Anaesthesist. 2007 Jun;56(6):604-11. German.</citation>
    <PMID>17522829</PMID>
  </reference>
  <reference>
    <citation>Sun W, Jeleniowski K, Zhao X, Shen P, Li D, Hammond JA. Thromboelastography (TEG)-based algorithm reduces blood product utilization in patients undergoing VAD implant. J Card Surg. 2014 Mar;29(2):238-43.</citation>
    <PMID>24734284</PMID>
  </reference>
  <reference>
    <citation>Wesley MC, McGowan FX, Castro RA, Dissanayake S, Zurakowski D, Dinardo JA. The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg. 2009 May;108(5):1425-9. doi: 10.1213/ane.0b013e3181981fbe.</citation>
    <PMID>19372315</PMID>
  </reference>
  <reference>
    <citation>Wang SC, Shieh JF, Chang KY, Chu YC, Liu CS, Loong CC, Chan KH, Mandell S, Tsou MY. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc. 2010 Sep;42(7):2590-3. doi: 10.1016/j.transproceed.2010.05.144.</citation>
    <PMID>20832550</PMID>
  </reference>
  <reference>
    <citation>Ak K, Isbir CS, Tetik S, Atalan N, Tekeli A, Aljodi M, Civelek A, Arsan S. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg. 2009 Jul-Aug;24(4):404-10. doi: 10.1111/j.1540-8191.2009.00840.x.</citation>
    <PMID>19583608</PMID>
  </reference>
  <reference>
    <citation>Zambruni A, Thalheimer U, Leandro G, Perry D, Burroughs AK. Thromboelastography with citrated blood: comparability with native blood, stability of citrate storage and effect of repeated sampling. Blood Coagul Fibrinolysis. 2004 Jan;15(1):103-7.</citation>
    <PMID>15166952</PMID>
  </reference>
  <reference>
    <citation>Subramanian A, Albert V, Saxena R, Agrawal D, Pandey RM. Establishing a normal reference range for thromboelastography in North Indian healthy volunteers. Indian J Pathol Microbiol. 2014 Jan-Mar;57(1):43-50. doi: 10.4103/0377-4929.130896.</citation>
    <PMID>24739830</PMID>
  </reference>
  <reference>
    <citation>Ji HW, Ma L, Gao XR, Liu N, Zhang Y, Wang Y, Ma ZX, Wang Y, Wang J, Fu X, Xiong Q, Qi HM. [Establishment of normal reference values for thromboelastography on Chinese population in Beijing]. Zhonghua Yi Xue Za Zhi. 2011 Apr 12;91(14):980-3. Chinese.</citation>
    <PMID>21609551</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2017</study_first_submitted>
  <study_first_submitted_qc>May 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>March 24, 2018</last_update_submitted>
  <last_update_submitted_qc>March 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Third Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>xy3transfusion</investigator_full_name>
    <investigator_title>Director, Blood transfusion</investigator_title>
  </responsible_party>
  <keyword>Thrombelastograghy</keyword>
  <keyword>reference ranges</keyword>
  <keyword>racial</keyword>
  <keyword>geographic</keyword>
  <keyword>Blood Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Transfusion Reaction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

